The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Open accessAbstract
The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) and incidence of coronary heart disease was eliminated by covariance adjustment. Using the proportional hazards model and adjusting for age, blood pressure, smoking, body mass index, and low-density lipoprotein cholesterol, we analyzed this relation separately in the Framingham Heart Study (FHS), Lipid Research Clinics Prevalence Mortality Follow-up Study (LRCF) and Coronary Primary Prevention Trial (CPPT), and Multiple Risk Factor Intervention Trial (MRFIT). In CPPT and MRFIT (both randomized trials in middle-age high-risk men), only the control groups were analyzed. A 1-mg/dl (0.026 mM) increment in HDLC was associated with a significant coronary heart disease risk decrement of 2% in men (FHS, CPPT, and MRFIT) and 3% in women (FHS). In LRCF, where only fatal outcomes were documented, a 1-mg/dl increment in HDLC was associated with significant 3.7% (men) and 4.7% (women) decrements in cardiovascular disease mortality rates. The 95% confidence intervals for these decrements in coronary heart and cardiovascular disease risk in the four studies overlapped considerably, and all contained the range 1.9-2.9%. HDLC levels were essentially unrelated to non-cardiovascular disease mortality. When differences in analytic methodology were eliminated, a consistent inverse relation of HDLC levels and coronary heart disease event rates was apparent in BRHS as well as in the four American studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In fact, a 1 mg/dL (0.026 mmol/L) increment in HDL-C levels was associated with a significant decrease in the risk of coronary heart disease of 2% in men and 3% in women.6”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [6]
In the citing paper
“Part of the protection that women have from CHD may be related to their high HDL-C levels.49,50”
From Associations of Glycemic Index and Load With Coronary Heart Disease Events: A Systematic Review and Meta‐Analysis of Prospective Cohorts (2012) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Self-citationHelsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Abell, L. L., Levy, B. B., Brodie, B. B., & Kendall, F. E. (1952) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50907-3 · Cited by 3,085
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
Self-citationEpidemiological approaches to heart disease: the Framingham study
Dawber, T. R., Meadors, G. F., & Moore, F. E. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.3.279 · Cited by 2,148
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
High density lipoprotein metabolism.
Eisenberg, S. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37713-0 · Cited by 1,212
Miller, N. E., Thelle, D. S., Førde, O. H., & Mjøs, O. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92274-7 · Cited by 1,206
Levy, R. I., Brensike, J. F., Epstein, S. E., Kelsey, S. F., Passamani, E. R., Richardson, J. M., Loh, I. K., Stone, N. J., Aldrich, R. F., & Battaglini, J. W. (1984) · Circulation · doi:10.1161/01.cir.69.2.325 · Cited by 437
Contractile performance of the hypertrophied ventricle in patients with systemic hypertension.
Takahashi, M., Sasayama, S., Kawai, C., & Kotoura, H. (1980) · Circulation · doi:10.1161/01.cir.62.1.116 · Cited by 302
High density lipoprotein as a protective factor against coronary heart disease. The Framingham study
(1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90899-3 · Cited by 275
Goldbourt, U., & Medalie, J. H. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112683 · Cited by 271
Goldbourt, U., Holtzman, E. J., & Neufeld, H. N. (1985) · BMJ · doi:10.1136/bmj.290.6477.1239 · Cited by 170
Green, M. S., & Symons, M. (1983) · Journal of Chronic Diseases · doi:10.1016/0021-9681(83)90165-0 · Cited by 169
Gordon, D. J., Ekelund, L. G., Karon, J. M., Probstfield, J. L., RUBENSTEIN, C., Sheffield, L. T., & Weissfeld, L. A. (1986) · Circulation · doi:10.1161/01.cir.74.2.252 · Cited by 162
Self-citationPocock, S., Shaper, A. G., Phillips, A. N., Walker, M., & Whitehead, T. P. (1986) · BMJ · doi:10.1136/bmj.292.6519.515 · Cited by 127
Watkins, L. O., Neaton, J. D., & Kuller, L. H. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90831-3 · Cited by 112
Self-citationALPHA LIPOPROTEIN (HDL) CHOLESTEROL IN THE SERUM AND THE RISK OF CORONARY HEART DISEASE AND DEATH
Keys, A. B. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90280-9 · Cited by 111
Anderson, K. M., Wilson, P. W. F., Garrison, R. J., & Castelli, W. P. (1987) · Atherosclerosis · doi:10.1016/0021-9150(87)90094-3 · Cited by 108
Self-citationEnger, S. C., Hjermann, I., FOSS, O. P., Helgeland, A., Holme, I., Leren, P., & Norum, K. R. (1979) · PubMed · Cited by 98
HDL Serum Cholesterol and 24–Year Mortality of Men in Finland
Keys, A. B., KARVONEN, M. J., Punsar, S., Menotti, A., Fidanza, F., & Farchi, G. (1984) · International Journal of Epidemiology · doi:10.1093/ije/13.4.428 · Cited by 74
Humes, R. A., Porter, C. B., Mair, D. D., Rice, M. J., Offord, K. P., Puga, F. J., Schaff, H. V., & Danielson, G. K. (1987) · PubMed · Cited by 69
High density lipoprotein is not a major risk factor for ischaemic heart disease in British men
Wynn, V., Crook, D., Godsland, I. F., Seed, M., & Shennan, N. M. (1986) · BMJ · doi:10.1136/bmj.292.6529.1200 · Cited by 6
Flagged first, then by citations
Research works printed but not linked: 8
- Miller NE, Forde OH, Thelle DS, Mjos OD: The Tromso Heart Study: High-density lipoprotein and coronary heart disease: A prospective case-control study. Lancet 1977; 1:965-970
- Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA (for the Lipid Research Clinics Program): High-density lipoprotein cholesterol and coronary heart disease in hyper- cholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986;74:1217-1225
- The Lipid Research Clinics Program Epidemiology Commit- tee: Plasma Lipid Distribution in Selected North American Populations: The Lipid Research Clinics Program Preva- lence Study. Circulation 1979;60:427-439
- The Lipid Research Clinics Program: The Coronary Primary Prevention Trial: Design and implementation. J Chronic Dis 1979;32:609-631
- The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduc- tion in incidence of coronary heart disease. JA1M 1984; 251:351-364
- The Multiple Risk Factor Intervention Trial Group: Statisti- cal design considerations in the NHLBI Multiple Risk Fac- tor Intervention Trial (MRFIT). J Chronic Dis 1977; 30:261-275
- Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: Risk factor changes and mortality results. JAMA 1982;248:1465-1477
- Shestov DB: Results of four years of follow-up of USSR populations, in USA-USSR First Lipoprotein Symposium. US Department of Health and Human Services Publication (NIH) 83-1966, Bethesda, Md, 1982, pp 391-407
Cited by
Sorted by citations
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimón, L., Badimón, L., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,792
Subcommittee, G. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,921
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Kodama, S. (2009) · JAMA · doi:10.1001/jama.2009.681 · Cited by 3,035
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Metadata
- Authors
- Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A.
- Affiliations
- National Institutes of Health (US)
- Venue
- Circulation
- Published
- 1989-01
- Volume
- 79
- Issue
- 1
- Pages
- 8-15
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2077760013
- Cited by
- 3,162
- References
- 27
- Citations by year
- 2026: 35 · 2025: 41 · 2024: 62 · 2023: 69 · 2022: 90 · 2021: 90 · 2020: 90 · 2019: 84 · 2018: 96 · 2017: 87 · 2016: 81 · 2015: 125 · 2014: 137 · 2013: 125 · 2012: 129
- FWCI
- 61.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01hv012156-034)
- National Heart, Lung, and Blood Institute (N01-HV32961, N01-HV 12156, N01-HV 12159)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, coronary artery disease, cardiovascular mortality, inverse association, Framingham Heart Study, Multiple Risk Factor Intervention Trial, British Regional Heart Study, cardiovascular risk, sex differences
- MeSH terms
- Adult, Aged, Cardiovascular Diseases, Clinical Trials as Topic, Female, Humans, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Regression Analysis, Risk Factors, Sex Factors, Statistics as Topic, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
